Oryzon Genomics S.A. (ORYZF)
OTCMKTS
· Delayed Price · Currency is USD
3.030
0.00 (0.00%)
At close: Apr 23, 2025
Oryzon Genomics Revenue
In the year 2024, Oryzon Genomics had annual revenue of 7.36M EUR, down -48.15%.
Revenue
7.36M EUR
Revenue Growth
-48.15%
P/S Ratio
31.26
Revenue / Employee
159.97K EUR
Employees
46
Market Cap
238.12M USD
Revenue Chart
* This company reports financials in EUR.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 7.36M | -6.83M | -48.15% |
| Dec 31, 2023 | 14.19M | -1.51M | -9.60% |
| Dec 31, 2022 | 15.70M | 5.08M | 47.88% |
| Dec 31, 2021 | 10.62M | 1.09M | 11.49% |
| Dec 31, 2020 | 9.52M | -756.51K | -7.36% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Endo Inc. | 1.76B |
| Veradigm | 588.02M |
| Glass House Brands | 200.90M |
| Elite Pharmaceuticals | 70.00M |
| Northwest Biotherapeutics | 1.38M |
| BioStem Technologies | 301.83M |
| American Oncology Network | 1.76B |
| Silence Therapeutics | 43.26M |
Oryzon Genomics News
- 8 days ago - ORYZON Continues to Strengthen its Patent Portfolio for Vafidemstat - GlobeNewsWire
- 6 weeks ago - ORYZON to Provide Corporate Progress Updates at Several Events in March-April - GlobeNewsWire
- 7 weeks ago - Oryzon Announces Publication of Study on Phelan-McDermid Syndrome (PMS) Patients, a Form of Autism, Paving the Way for a Novel Personalized Medicine Approach with Vafidemstat - GlobeNewsWire
- 2 months ago - ORYZON Announces the Voting Results of February 2025 Extraordinary General Shareholders' Meeting - GlobeNewsWire
- 2 months ago - ORYZON Reports Financial Results and Corporate Update for Quarter Ended December 31, 2024 - GlobeNewsWire
- 2 months ago - ORYZON Announces Journal Publication of Final Phase IIa REIMAGINE Results with Vafidemstat in Psychiatry and Clinical Neurosciences - GlobeNewsWire
- 3 months ago - ORYZON to Reshape Its Board of Directors at the Upcoming Shareholders' Meeting - GlobeNewsWire
- 3 months ago - ORYZON announces first patient dosed in an Investigator-initiated Phase I study of iadademstat in myelodysplastic syndrome - GlobeNewsWire